IMR Press / EJGO / Volume 37 / Issue 4 / DOI: 10.12892/ejgo2847.2016

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
The outcomes of radiotherapy in patients with ovarian carcinoma
Show Less
1 Radiotherapy Department, Oncology Centre in Bydgoszcz, Bydgoszcz, Poland
2 The Chair and Clinic of Oncology and Brachytherapy, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
Eur. J. Gynaecol. Oncol. 2016, 37(4), 461–468;
Published: 10 August 2016

Relapses of ovarian cancer have poor prognosis, overall survival (OS) after recurrence depends on patient's performance status, histological cell type, size and number of the relapse, and duration of the platinum-free interval. Pelvis, peritoneum, pleural effusion, liver, lung, lymph nodes, and central nervous system are the most frequent sites of relapse. The standard treatment for ovarian cancer is a combination of surgery and chemotherapy. This retrospective study aimed to describe incidence, characteristics, outcomes and prognostic factors of patients with ovarian cancer underwent radiotherapy. Results: In 47 with ovarian cancer underwent radiotherapy. Treatment modalities were radiotherapy 8- 56 Gy. After optimal treatment the authors observed complete remission in seven patients, and progression and/or metastases in 40 patients. The present study confirmed that patients with low advancement stage had better prognoses than patients with advanced disease, as confirmed by OS rates in groups T1 vs. T3 (p = 0.066) and T3 vs. T4 (p = 0.066). What was interesting was that the disease-free survival (DFS) in the group of patients with T3 cancer was longer than in the group of patients with T1 cancer. Time to marker progression (Ca 125) was longer in groups with FIGO Stage I vs. II and I vs. III (p = 0.016, p = 0.044), while the time to progression in FIGO Stage II cancer patients was shorter than in FIGO Stage III cancer patients. An interesting result was also obtained in the analysis of 36-month survival where a larger number of patients without the disease symptoms had T3 Stage cancer. New prospective studies, designed to include the aspects of target volumes, total doses and fraction doses, together with the use of state of the art planning techniques, and therapeutic instrumentation are required.
Back to top